癌癥(ISSN 2072 - 6694;CODEN: CANCCT)是一份開放獲取的腫瘤雜志，每月由MDPI在線出版。《癌癥》(ISSN 2072-6694)是一本國際性的、同行評審的腫瘤學(xué)開放獲取期刊。它發(fā)表評論、定期研究論文和簡短的交流。我們的目標(biāo)是鼓勵(lì)科學(xué)家盡可能詳細(xì)地發(fā)表他們的實(shí)驗(yàn)和理論結(jié)果。這篇論文的篇幅沒有限制。必須提供完整的實(shí)驗(yàn)細(xì)節(jié)，以便重現(xiàn)結(jié)果。此外，這本雜志還有一些獨(dú)特的特點(diǎn):特別歡迎有關(guān)研究建議和研究想法的手稿有關(guān)計(jì)算和實(shí)驗(yàn)程序的全部細(xì)節(jié)的電子文件或軟件，如不能正常發(fā)表，可作為補(bǔ)充材料存放我們也接受與更廣泛的讀者交流有關(guān)公共資金資助的研究項(xiàng)目的手稿我們接受有意義但結(jié)果消極的研究。雖然有很多期刊關(guān)注癌癥研究，但沒有一本積極接受負(fù)面結(jié)果。結(jié)果，大多數(shù)負(fù)面數(shù)據(jù)最終都不在公共領(lǐng)域，即使這些數(shù)據(jù)是有意義的負(fù)面數(shù)據(jù)，而且研究設(shè)計(jì)得很好。通過接受這些消極的結(jié)果，我們的雜志鼓勵(lì)科學(xué)家們分享這些數(shù)據(jù)，這樣他們就不需要重復(fù)別人已經(jīng)做過的實(shí)驗(yàn)。開放存取-免費(fèi)為讀者，出版費(fèi)用由作者或他們的機(jī)構(gòu)支付。快速出版:稿件經(jīng)過同行評審，并在投稿后約29天向作者提供第一個(gè)決定;發(fā)表驗(yàn)收時(shí)間為6天(2016年發(fā)表論文中位數(shù))。對于癌癥(ISSN 2072-6694)，作者被要求為每一篇處理過的論文支付850瑞士法郎(瑞士法郎)的費(fèi)用，但前提是這篇文章在同行評審和可能的手稿修改后被接受發(fā)表在本刊上。請注意，許多國家和私人研究資助機(jī)構(gòu)和大學(xué)都明確為源自資助研究項(xiàng)目的文章支付此類費(fèi)用。參加MDPI會(huì)員計(jì)劃的機(jī)構(gòu)的作者可享受折扣。除瑞士法郎(CHF)外，我們還接受歐元(EUR)、美元(USD)或人民幣(CNY)的費(fèi)用支付。現(xiàn)行匯率按XE + 5%的匯率計(jì)算。

Cancers (ISSN 2072-6694; CODEN: CANCCT) is an open access journal of oncology published monthly online by MDPI.Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, unique features of this journal: manuscripts regarding research proposals and research ideas will be particularly welcomed electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material we also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done. Open Access - free for readers, with publishing fees paid by authors or their institutions. Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 29 days after submission; acceptance to publication is undertaken in 6 days (median values for papers published in this journal in 2016). For Cancers (ISSN 2072-6694), authors are asked to pay a fee of 850 CHF (Swiss Francs) per processed paper, but only if the article is accepted for publication in this journal after peer-review and possible revision of the manuscript. Note that many national and private research funding organizations and universities explicitly cover such fees for articles originated in funded research projects. Discounts are available for authors from institutes that participate with MDPI''s membership program. In addition to Swiss Francs (CHF), we also accept payment of the fees in Euros (EUR), US Dollars (USD) or Chinese Yuan (CNY). Current exchange rates published at XE plus 5% exchange commission apply.